-
Supreme Court Calls For Some Deference In Claim Construction Standard Of Review – Courtesy (Pharma Patents)
POSTED BY COURTENAY C. BRINCKERHOFF ON 22 JANUARY 2015POSTED IN CLAIM CONSTRUCTION;SUPREME COURT DECISIONSOn January 20, 2015, the Supreme Court issued its...
-
It’s not just big pharma that wants to see IPR reform in US patent legislation – By Richard Lloyd
For over an hour yesterday, as the Senate Judiciary Committee hearing on the recently introduced PATENT Act unfolded, it seemed like we were...
-
Orphan drug market to reach $176bn by 2020 – Courtesy ( PMLiVe)
pharmacistThe global orphan drug market is expected to account for 19% of all branded prescription drug sales by 2020,...
-
Channel strategy and orphan drugs – Courtesy (PMLiVe)
Channel strategy and orphan drugsA channel strategy is a plan for guiding decisions about a product’s distribution channel, ie...
-
RCEs and the New USPTO Patent Term Adjustment Rules – Courtesy (Global IP Matters)
On January 9, 2015, the Federal Register published final rules implementing changes to patent term adjustment (PTA) in view of Novartis v....
-
Merck scores victory in India patent battle over top diabetes meds! – Courtesy (Fierce Pharma)
In a potentially promising sign for Western drugmakers, Merck ($MRK) scored a victory in its patent battle with India’s Glenmark...
-
Wyeth denied patent for cancer drug – Courtesy ( The Financial Express)
Wyeth, which was acquired by US- based pharma major Pfizer Inc, has suffered a major setback in India with...
-
Patents Against People: How Drug Companies Price Patients out of Survival – Courtesy (Dissent)
As our television screens toggle between pundits squabbling over Obamacare’s insurance rules and ads for erectile dysfunction remedies, another...
